# Supplementary material for: **Exploratory Cost-Effectiveness Analysis of Drug Therapy Added to Lifestyle Intervention for Prediabetes in the German Statutory Health System**

A functional Excel copy of the model used for this study is being provided as download at <https://www.hs-heilbronn.de/de/downloads-3758ab4c9430bf0e>


This model allows interested readers to modify core parameters of the analysis.

Ein Bild, das Text, Screenshot, Design enthält.

KI-generierte Inhalte können fehlerhaft sein.

Table 1: Comparison of ICER values between European QoL value set and US American QoL value set using females from the base cohort.

|  |  |  |
| --- | --- | --- |
| Strategy | ICER Europe  [Cost/QalyG] | ICER USA  [Cost/QalyG] |
| Lifestyle (Base case) |  |  |
| Metformin | Dominant | Dominant |
| Tirzepatide | 69,982.04 | 33,075.91 |
| Semaglutide | 175,771.56 | 84,234.04 |




Figure 1: Tornado diagram comparing Tirzepatide Tx vs. Metformin Tx in the female base case cohort.

Figure 2: Tornado diagram comparing Metformin Tx vs. Lifestyle base case Tx in the female base case cohort.





Figure 3: Tornado diagram comparing Tirzepatide Tx vs. Metformin Tx in the male base case cohort.

Figure 4: Tornado diagram comparing Semaglutide Tx vs. Metformin Tx in the male base case cohort.




Figure 5: Tornado diagram comparing Metformin Tx vs. Lifestyle base case Tx in the male base case cohort.